The company announced that all patients with acute myeloid leukemia treated with its lead candidate, mipletamig, achieved remission within 30 days in a Phase 1b trial.
SEATTLE, WASHINGTON / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology...
Two of three patients achieved both complete remission and MRD-negative status
Powered by Aptevo's proprietary ADAPTIR-FLEX®platform, antibody innovation targeting difficult-to-treat cancers
SEATTLE, WA / ACCESSWIRE / November 29, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), today announced that it will conduct a reverse stock split of its outstanding shares of...
Aptevo's Peter Pavlik, PhD, to chair a session on "Bi and Multispecific Biologics" and will also give talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR™ Platform"...
Developing innovative bispecific antibodies for monotherapy and combination with the potential to expand the frontiers of cancer treatment
Potential to redefine frontline AML treatment being evaluated in clinic: Mipletamig, CD3 x CD123 bispecific, in combination with standard of care, offers a multi-mechanism strategy for potential improved...
Aptevo's lead candidate APVO436 (mipletamig) to be evaluated in combination with standard of care venetoclax and azacitidine
Cohort 1 Combination Therapy Arm Shows 36% Remission Rate Among Response-evaluable Patients Treated to Date